WallStSmart

GlucoTrack Inc (GCTK)vsStryker Corporation (SYK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

SYK leads profitability with a 13.8% profit margin vs 0.0%. SYK earns a higher WallStSmart Score of 57/100 (C).

GCTK

Avoid

26

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 4.5
Piotroski: 2/9Altman Z: -34.50

SYK

Buy

57

out of 100

Grade: C

Growth: 5.3Profit: 7.5Value: 4.0Quality: 6.5
Piotroski: 2/9Altman Z: 2.18
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for GCTK.

SYKSignificantly Overvalued (-38.2%)

Margin of Safety

-38.2%

Fair Value

$235.85

Current Price

$318.79

$82.94 premium

UndervaluedFair: $235.85Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

GCTK1 strengths · Avg: 10.0/10
Debt/EquityHealth
-0.0110/10

Conservative balance sheet, low leverage

SYK3 strengths · Avg: 8.3/10
Market CapQuality
$111.11B9/10

Large-cap with strong market position

Operating MarginProfitability
20.3%8/10

Strong operational efficiency at 20.3%

Free Cash FlowQuality
$1.22B8/10

Generating 1.2B in free cash flow

Areas to Watch

GCTK4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$650,5103/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

SYK3 concerns · Avg: 3.0/10
P/E RatioValuation
31.1x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-11.7%2/10

Earnings declined 11.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : GCTK

The strongest argument for GCTK centers on Debt/Equity.

Bull Case : SYK

The strongest argument for SYK centers on Market Cap, Operating Margin, Free Cash Flow. PEG of 1.37 suggests the stock is reasonably priced for its growth.

Bear Case : GCTK

The primary concerns for GCTK are Revenue Growth, EPS Growth, Market Cap.

Bear Case : SYK

The primary concerns for SYK are P/E Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

SYK carries more volatility with a beta of 0.78 — expect wider price swings.

SYK is growing revenue faster at 7.6% — sustainability is the question.

SYK generates stronger free cash flow (1.2B), providing more financial flexibility.

Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SYK scores higher overall (57/100 vs 26/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

GlucoTrack Inc

HEALTHCARE · MEDICAL DEVICES · USA

GlucoTrack, Inc., a medical device company, designs, develops and markets noninvasive glucose monitoring devices for people with diabetes and prediabetes in Europe and Asia Pacific. The company is headquartered in Or Yehuda, Israel.

Visit Website →

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Want to dig deeper into these stocks?